Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. [electronic resource]
Producer: 20151112Description: 1835-44 p. digitalISSN:- 1533-4406
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Exanthema -- chemically induced
- Female
- Follow-Up Studies
- Humans
- Induction Chemotherapy
- Intention to Treat Analysis
- Lenalidomide
- Lymphoma, Mantle-Cell -- drug therapy
- Maintenance Chemotherapy
- Male
- Middle Aged
- Neutropenia -- chemically induced
- Quality of Life
- Rituximab
- Survival Analysis
- Thalidomide -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.